List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8708859/publications.pdf Version: 2024-02-01



#	ARTICLE	١٢	CITATIONS
1	Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nature Reviews Immunology, 2022, 22, 124-138.	22.7	81
2	Guidelines for the management of mature T―and natural killerâ€eell lymphomas (excluding cutaneous) Tj ETQ 196, 507-522.	)q0 0 0 rgB 2.5	T /Overlock 1 12
3	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. Journal of Clinical Oncology, 2022, 40, 2203-2212.	1.6	10
4	Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. Cancers, 2022, 14, 145.	3.7	7
5	Radiotherapy–Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?. Cancers, 2021, 13, 457.	3.7	27
6	4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2021, 22, 332-340.	10.7	51
7	Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. Clinical Cancer Research, 2021, 27, 4353-4366.	7.0	27
8	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 3591-3601.	1.6	21
9	Progress and pitfalls with the use of image-guided personalised approaches in lymphoma. British Journal of Radiology, 2021, 94, 20210609.	2.2	3
10	TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S411.	0.4	0
11	Lymphoma: advances in imaging and radiotherapy – introductory editorial. British Journal of Radiology, 2021, 94, 20219005.	2.2	2
12	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood, 2021, 138, 135-135.	1.4	2
13	ls it time to rethink checkpoint blockade therapy in nonâ€Hodgkin lymphoma?. British Journal of Haematology, 2020, 191, 13-14.	2.5	1
14	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2020, 4, 4091-4101.	5.2	33
15	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiation Oncology, 2020, 15, 254.	2.7	62
16	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. International Journal of Radiation Oncology Biology Physics, 2020, 108, 27-37.	0.8	22
17	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
18	The investigation and management of follicular lymphoma. British Journal of Haematology, 2020, 191, 363-381.	2.5	14

#	Article	IF	CITATIONS
19	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
20	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
21	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. Blood Advances, 2020, 4, 203-206.	5.2	15
22	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. Cancers, 2020, 12, 2835.	3.7	8
23	Scientific rationale underpinning theÂdevelopment of biosimilar rituximab in hematological cancers and inflammatory diseases. Future Oncology, 2019, 15, 4223-4234.	2.4	8
24	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. EJNMMI Research, 2019, 9, 18.	2.5	9
25	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. Journal of Clinical Oncology, 2019, 37, 1732-1741.	1.6	38
26	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. International Reviews of Immunology, 2019, 38, 79-91.	3.3	3
27	Immunogenic Effects of Radiotherapy for Bladder Cancer. Clinical Oncology, 2019, 31, e26.	1.4	0
28	CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM. Hematological Oncology, 2019, 37, 488-490.	1.7	0
29	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology, 2019, 180, 496-526.	1.5	111
30	The management of primary mediastinal B ell lymphoma: a British Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 402-409.	2.5	15
31	Clinical Development of Novel Drug–Radiotherapy Combinations. Clinical Cancer Research, 2019, 25, 1455-1461.	7.0	42
32	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
33	Patient and physician preferences for firstâ€line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. British Journal of Haematology, 2019, 184, 202-214.	2.5	35
34	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood, 2018, 131, 2120-2124.	1.4	56
35	Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma — Introducing the PERM Trial. Clinical Oncology, 2018, 30, 201-203	1.4	6
36	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.8	46

#	Article	IF	CITATIONS
37	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 652-669.	0.8	71
38	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Annals of Oncology, 2018, 29, 301-310.	1.2	98
39	Recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology, 2018, 29, 1069-1070.	1.2	2
40	Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leukemia and Lymphoma, 2018, 59, 1413-1419.	1.3	16
41	The anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancer. Nature Reviews Urology, 2018, 15, 251-259.	3.8	27
42	A novel approach to low dose total skin electron beam therapy (TSEBT). European Journal of Cancer, 2018, 101, S31.	2.8	0
43	How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?. British Journal of Haematology, 2018, 182, 163-164.	2.5	1
44	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv19-iv29.	1.2	243
45	Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity. Leukemia and Lymphoma, 2018, 59, 2519-2520.	1.3	0
46	LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up. Blood, 2018, 132, 2879-2879.	1.4	11
47	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. Blood, 2018, 132, 997-997.	1.4	3
48	lmmune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?. Clinical Oncology, 2017, 29, 207-217.	1.4	6
49	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia, 2017, 31, 1611-1621.	7.2	37
50	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clinical Cancer Research, 2017, 23, 5514-5526.	7.0	282
51	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 2017, 130, 2709-2717.	1.4	176
52	Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. European Journal of Haematology, 2017, 99, 553-558.	2.2	16
53	Akt inhibition improves longâ€ŧerm tumour control following radiotherapy by altering the microenvironment. EMBO Molecular Medicine, 2017, 9, 1646-1659.	6.9	12
54	The influence of radiation in the context of developing combination immunotherapies in cancer. , 2017, 5, 115-122.	2.3	12

#	Article	IF	CITATIONS
55	Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer. Translational Cancer Research, 2017, 6, S553-S556.	1.0	1
56	Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Oncotarget, 2016, 7, 17035-17046.	1.8	25
57	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5â€year results from a <scp>UK</scp> National Cancer Research Institute Lymphoma Group study. British Journal of Haematology, 2016, 173, 274-282.	2.5	12
58	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v91-v102.	1.2	102
59	Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. Journal of Clinical Oncology, 2016, 34, 1443-1447.	1.6	31
60	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia and Lymphoma, 2016, 57, 1269-1280.	1.3	4
61	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. Clinical Oncology, 2016, 28, 726-731.	1.4	10
62	Guidelines for the management of diffuse large B ell lymphoma. British Journal of Haematology, 2016, 174, 43-56.	2.5	125
63	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. British Journal of Radiology, 2016, 89, 20160472.	2.2	32
64	Immunotherapy with radiotherapy in urological malignancies. Current Opinion in Urology, 2016, 26, 514-522.	1.8	5
65	Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. Cancer Immunology Research, 2016, 4, 621-630.	3.4	50
66	Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 2016, 13, 627-642.	27.6	230
67	177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. Blood, 2016, 128, 1780-1780.	1.4	2
68	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2993-2993.	1.4	5
69	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 4144-4144.	1.4	9
70	Abstract SY31-02: The interplay of radiotherapy with the tumour microenvironment: Novel opportunities to overcome adaptive resistance. , 2016, , .		0
71	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treatment Reviews, 2015, 41, 503-510.	7.7	482
72	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 144-152.	0.8	18

#	Article	IF	CITATIONS
73	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From theÂInternational Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 32-39.	0.8	150
74	Personalised approach to treating early Hodgkin's lymphoma. BMJ, The, 2015, 350, h2927-h2927.	6.0	2
75	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.8	303
76	Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy, 2015, 15, 787-801.	3.1	40
77	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 1598-1607.	27.0	619
78	PET-Directed Therapy for Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 373, 392-392.	27.0	16
79	Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews, 2015, 41, 784-792.	7.7	52
80	The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncolmmunology, 2015, 4, e1016709.	4.6	78
81	Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right?. Clinical Oncology, 2015, 27, 454-456.	1.4	0
82	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. Clinical Oncology, 2015, 27, 696-699.	1.4	11
83	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia and Lymphoma, 2015, 56, 703-710.	1.3	29
84	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. Blood, 2015, 126, 1537-1537.	1.4	5
85	Brentuximab Vedotin in Combination with Chp in Patients (Pts) with Newly-Diagnosed Cd30+ Peripheral T-Cell Lymphomas (Ptcl): 2-Year Follow-Up. Annals of Oncology, 2014, 25, iv327.	1.2	0
86	Phase 3 Trial of Brentuximab Vedotin and Chp Versus Chop in the Frontline Treatment of Patients (Pts) with Cd30+ Mature T-Cell Lymphomas (Mtcl). Annals of Oncology, 2014, 25, iv338.	1.2	0
87	Consensus guidelines for the detection of immunogenic cell death. Oncolmmunology, 2014, 3, e955691.	4.6	686
88	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and) Tj ETQq0 0 0	rgBT2/Ovei	<sup>-</sup> lo <b>sk</b> 10 Tf 50
89	New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. Leukemia and Lymphoma, 2014, 55, 3-4.	1.3	1

<sup>90</sup>Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. Journal of the National<br/>Cancer Institute, 2014, 106, .6.348

#	Article	IF	CITATIONS
91	Guideline on the management of primary resistant and relapsed classical <scp>H</scp> odgkin lymphoma. British Journal of Haematology, 2014, 164, 39-52.	2.5	27
92	Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited‣tage Diffuse Large Bâ€Cell Lymphoma of the Bone (the IELSCâ€14 Study)― Oncologist, 2014, 3 1289-1289.	193.7	1
93	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 <sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study. Journal of Clinical Oncology, 2014, 32, 3137-3143.	1.6	153
94	4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncology, The, 2014, 15, 457-463.	10.7	191
95	Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy. Clinical Oncology, 2014, 26, 266-276.	1.4	12
96	A novel systemically administered tollâ€like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. International Journal of Cancer, 2014, 135, 820-829.	5.1	41
97	Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opinion on Biological Therapy, 2014, 14, 1507-1517.	3.1	18
98	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii70-iii75.	1.2	257
99	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research, 2014, 74, 5458-5468.	0.9	1,014
100	Fractionated <sup>90</sup> Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2014, 32, 212-218.	1.6	57
101	Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1. International Journal of Radiation Oncology Biology Physics, 2014, 90, S776.	0.8	11
102	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	0.8	259
103	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2014, 89, 854-862.	0.8	479
104	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2014, 124, 3095-3095.	1.4	14
105	Abstract 5034: The antitumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. , 2014, , .		2
106	Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leukemia and Lymphoma, 2013, 54, 2008-2015.	1.3	11
107	Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood, 2013, 121, 251-259.	1.4	130
108	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2013, 168, 192-200.	1.5	81

#	Article	IF	CITATIONS
109	Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. Cell Death and Differentiation, 2013, 20, 765-773.	11.2	18
110	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukemia and Lymphoma, 2013, 54, 2531-2533.	1.3	120
111	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. British Journal of Cancer, 2013, 108, 2399-2406.	6.4	49
112	The induction of immunogenic cell death by type II antiâ€ <scp>CD</scp> 20 monoclonal antibodies has mechanistic differences compared with type I rituximab. British Journal of Haematology, 2013, 162, 842-845.	2.5	19
113	XVII. Radiotherapy in early stage Hodgkin lymphoma. Hematological Oncology, 2013, 31, 92-95.	1.7	4
114	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. British Journal of Cancer, 2013, 109, 2566-2573.	6.4	35
115	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. British Journal of Cancer, 2013, 109, 2560-2565.	6.4	8
116	Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncolmmunology, 2013, 2, e24501.	4.6	4
117	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica, 2013, 98, 611-614.	3.5	88
118	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2013, 122, 1809-1809.	1.4	24
119	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	1.4	6
120	Radiotherapy physics research in the UK: challenges and proposed solutions. British Journal of Radiology, 2012, 85, 1354-1362.	2.2	11
121	Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 2012, , 99.	2.7	0
122	Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood, 2012, 119, 3523-3533.	1.4	106
123	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2012, 30, 2190-2196.	1.6	890
124	Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations. Expert Opinion on Biological Therapy, 2012, 12, 543-545.	3.1	16
125	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology, 2012, 159, 541-564.	2.5	127
126	Guidelines on the investigation and management of follicular lymphoma. British Journal of Haematology, 2012, 156, 446-467.	2.5	58

#	Article	IF	CITATIONS
127	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Blood, 2012, 120, 2745-2745.	1.4	6
128	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 2012, 120, 3701-3701.	1.4	7
129	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood, 2012, 120, 60-60.	1.4	32
130	New antibody drug treatments for lymphoma. Expert Opinion on Biological Therapy, 2011, 11, 623-640.	3.1	15
131	Radioimmunotherapy in follicular lymphoma. Best Practice and Research in Clinical Haematology, 2011, 24, 279-293.	1.7	29
132	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology, 2011, 100, 86-92.	0.6	309
133	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 2011, 117, 4519-4529.	1.4	270
134	The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood, 2011, 117, 2993-3001.	1.4	117
135	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer, 2011, 104, 719-725.	6.4	48
136	Current Developments in Specialty Training. Clinical Oncology, 2011, 23, 431-433.	1.4	1
137	X. When should radiotherapy be used in lymphoma?. Annals of Oncology, 2011, 22, iv57-iv60.	1.2	1
138	YY1 expression predicts favourable outcome in follicular lymphoma. Journal of Clinical Pathology, 2011, 64, 125-129.	2.0	33
139	Tumor cell embryonality and the ploidy number 32n: Is it a developmental checkpoint?. Cell Cycle, 2011, 10, 1873-1874.	2.6	9
140	Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer, 2011, 105, 628-639.	6.4	140
141	Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab. Blood, 2011, 118, 1644-1644.	1.4	9
142	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. Blood, 2011, 118, 3091-3091.	1.4	6
143	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood, 2011, 118, 443-443.	1.4	11
144	Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species. Blood, 2011, 118, 1651-1651.	1.4	0

#	Article	IF	CITATIONS
145	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. Blood, 2010, 116, 3373-3374.	1.4	8
146	New insights into the mechanisms of action of radioimmunotherapy in lymphoma. Journal of Pharmacy and Pharmacology, 2010, 60, 987-998.	2.4	4
147	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Journal of Immunological Methods, 2010, 360, 30-38.	1.4	25
148	Radiotherapy Research Priorities for the UK. Clinical Oncology, 2010, 22, 707-709.	1.4	8
149	Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?. Journal of Clinical Oncology, 2010, 28, 2944-2946.	1.6	34
150	A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. Clinical Radiology, 2010, 65, 720-728.	1.1	9
151	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2010, 116, 961-961.	1.4	13
152	Anti-HLA-DR Monoclonal Antibody Evokes a Novel Non-Apoptotic Cell Death Pathway In Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3245-3245.	1.4	0
153	Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma. Clinical Medicine Therapeutics, 2009, 1, CMT.S2124.	0.1	0
154	Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma. Current Oncology Reports, 2009, 11, 363-370.	4.0	4
155	Phase 1/2 study of fractionated 1311-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 2009, 113, 1412-1421.	1.4	79
156	When is a predose a dose too much?. Blood, 2009, 113, 6034-6035.	1.4	4
157	Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. Journal of Clinical Investigation, 2009, 119, 2143-59.	8.2	149
158	New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma Blood, 2009, 114, 725-725.	1.4	5
159	Abstract C184: Validation of an ELISA for the determination of Rituximab pharmacokinetics in clinical trials subjects. , 2009, , .		0
160	Endopolyploidy in irradiated p53â€deficient tumour cell lines: Persistence of cell division activity in giant cells expressing Auroraâ€B kinase. Cell Biology International, 2008, 32, 1044-1056.	3.0	69
161	How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?. Leukemia and Lymphoma, 2008, 49, 1263-1273.	1.3	9
162	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. European Journal of Cancer, 2008, 44, 366-373.	2.8	25

#	Article	IF	CITATIONS
163	Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase–Dependent Cell Death that Overcomes Resistance to Apoptosis. Clinical Cancer Research, 2008, 14, 4925-4934.	7.0	31
164	Current treatment approaches for diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2008, 49, 663-676.	1.3	20
165	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR–based gene expression profiling. Blood, 2008, 111, 4764-4770.	1.4	84
166	Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies. Blood, 2008, 112, 883-883.	1.4	1
167	A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. Blood, 2008, 112, 4828-4828.	1.4	0
168	Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. Cancer Research, 2007, 67, 1335-1343.	0.9	10
169	Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 3440-3447.	1.6	159
170	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 2007, 109, 4655-4662.	1.4	200
171	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 2007, 110, 54-58.	1.4	171
172	Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration Blood, 2007, 110, 359-359.	1.4	1
173	A50 iodogen labelling method preserves immunoreactivity of high specific activity 131I-labelled rituximab for clinical RIT. Nuclear Medicine Communications, 2006, 27, 293-294.	1.1	1
174	A21 The microscopic tumour biodistribution of 1311-labelled mAb is critical in predicting successful radioimmunotherapy of lymphoma. Nuclear Medicine Communications, 2006, 27, 286.	1.1	0
175	Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer, 2006, 6, 6.	2.6	84
176	Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer, 2006, 107, 686-695.	4.1	35
177	Macrophage Depletion Can Enhance Combined Radiation and Anti-CD40 Monoclonal Antibody Therapy of B-Cell Lymphoma Blood, 2006, 108, 2501-2501.	1.4	0
178	Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation Blood, 2006, 108, 2508-2508.	1.4	0
179	Anti-CD40: Janus or gatekeeper?. Blood, 2005, 106, 2595-2596.	1.4	1
180	Segregation of genomes in polyploid tumour cells following mitotic catastrophe. Cell Biology International, 2005, 29, 1005-1011.	3.0	98

#	Article	IF	CITATIONS
181	What's new in the management of cutaneous T-cell lymphoma?. Clinical Oncology, 2005, 17, 174-184.	1.4	13
182	Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody–Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells. Cancer Research, 2005, 65, 7493-7501.	0.9	9
183	Anti-CD40 monoclonal antibody. Leukemia and Lymphoma, 2005, 46, 1105-1113.	1.3	24
184	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2004, 22, 157-165.	1.6	523
185	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 125, 294-317.	2.5	134
186	Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood, 2004, 103, 1485-1494.	1.4	21
187	Apparent modulation of CD20 by rituximab: an alternative explanation. Blood, 2004, 103, 3989-3991.	1.4	21
188	A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood, 2004, 104, 2540-2542.	1.4	44
189	Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL) Blood, 2004, 104, 131-131.	1.4	2
190	Cyclophosphamide Induced CD11b+ Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma Blood, 2004, 104, 3280-3280.	1.4	0
191	Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. Journal of Cell Science, 2003, 116, 4095-4106.	2.0	94
192	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell–dependent immunity to B-cell lymphoma. Blood, 2003, 102, 1449-1457.	1.4	81
193	Nuclear envelope-limited chromatin sheets are part of mitotic death. Histochemistry and Cell Biology, 2002, 117, 243-255.	1.7	31
194	Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial. International Journal of Radiation Oncology Biology Physics, 2002, 54, 92.	0.8	1
195	Predictors of survival for patients with brain metastases: results of a randomized phase III trial. International Journal of Radiation Oncology Biology Physics, 2002, 54, 93.	0.8	1
196	Cervical Neuropathy Following Mantle Radiotherapy. Clinical Oncology, 2002, 14, 468-471.	1.4	13
197	Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium. International Journal of Radiation Oncology Biology Physics, 2001, 51, 135-136.	0.8	2
198	Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium. International Journal of Radiation Oncology Biology Physics, 2001, 51, 410.	0.8	0

#	Article	IF	CITATIONS
199	Trastuzumab: Designer Drug or Fashionable Fad?. Clinical Oncology, 2001, 13, 427-433.	1.4	1
200	Antibody therapy of lymphoma. Expert Opinion on Pharmacotherapy, 2001, 2, 953-961.	1.8	13
201	Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy. Clinical Oncology, 2001, 13, 372-377.	1.4	2
202	RELEASE OF MITOTIC DESCENDANTS BY GIANT CELLS FROM IRRADIATED BURKITT'S LYMPHOMA CELL LINES. Cell Biology International, 2000, 24, 635-648.	3.0	107
203	The Emerging Role Of Radioimmunotherapy In Haematological Malignancies. British Journal of Haematology, 2000, 108, 679-688.	2.5	29
204	A New in Vivo and in Vitro B cell Lymphoma Model, π-BCL1. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 571-580.	1.0	15
205	Radioimmunotherapy in the π-BCL1B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 581-591.	1.0	10
206	POLYPLOID GIANT CELLS PROVIDE A SURVIVAL MECHANISM FOR p53 MUTANT CELLS AFTER DNA DAMAGE. Cell Biology International, 2000, 24, 621-633.	3.0	147
207	Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy. Current Pharmaceutical Design, 2000, 6, 1399-1418.	1.9	26
208	The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma. Blood, 1999, 94, 233-243.	1.4	27
209	The Junior Radiology Forum: What do the trainees think about the future of oncology training?. Clinical Oncology, 1998, 10, 71-72.	1.4	2
210	The future of oncology training: From the trainees' perspective. Clinical Oncology, 1998, 10, 84-91.	1.4	6
211	Radiation-induced apoptosis. Clinical Oncology, 1998, 10, 3-13.	1.4	15
212	Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clinical Oncology, 1996, 8, 257-258.	1.4	62
213	Arthritis and carcinoma Annals of the Rheumatic Diseases, 1993, 52, 86-86.	0.9	5
214	Euthanasia BMJ: British Medical Journal, 1992, 305, 1225-1225.	2.3	1
215	Effect of dihydroxy-bile salts on the interaction of trypsin and trypsin inhibitors. Biochemical Society Transactions, 1988, 16, 168-168.	3.4	0